A Phase 2 interventional study of Rosuvastatin and Rosuvastatin in Diabetes Mellitus, sponsored by AstraZeneca. Completed at 116 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-09-01.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing rosuvastatin in Diabetes Mellitus — 1 open to participants now, 1 under way, none of them phase 3. rosuvastatin · Diabetes Mellitus.
Among the 17 studies testing rosuvastatin in Diabetes Mellitus, this one is the 4th largest by enrollment, is one of 4 that started in 2006, is one of 3 in phase 2, and was the 1st registered.
8,294 studies on the registry are indexed under Diabetes Mellitus; 1,073 are open to participants now.
Browse Diabetes Mellitus studies →1 of the 17 studies testing rosuvastatin in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:
Shaheed Benazir Bhutto University Sheringal Dir Upper · Sites in Pakistan
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →
Of the 650 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 89 take children under 18; 182 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 353 is above the median of 80 across 6,026 interventional studies indexed under Diabetes Mellitus.
Median enrollment 108 across the 17 interventional studies. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 17 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
122 studies in Diabetes Mellitus by AstraZeneca: none open now, none under way, none of them phase 3. Of 121 finished, 58 (48%) have results posted.
Among the 122 studies in Diabetes Mellitus by AstraZeneca, this one is the 34th largest by enrollment of the 91 interventional ones that give a count, is one of 14 that started in 2006, is one of 14 in phase 2, and was the 20th registered.
AstraZeneca’s Diabetes Mellitus studies by the year they started, since 2002.
1 of the studies testing rosuvastatin in Diabetes Mellitus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07378293Shaheed Benazir Bhutto University Sheringal Dir UpperEffects of Selected Statins on Blood Glucose Levels in Healthy Volunteers | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing rosuvastatin in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 122 in Diabetes Mellitus:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in patients with Type 1 or 2 diabetes with moderate proteinuria and hypercholesterolaemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Rosuvastatin 10 mg
Drug: Rosuvastatin
Rosuvastatin 40 mg
Drug: Rosuvastatin
Atorvastatin 80 mg
Drug: Atorvastatin
10 mg oral dose administered once daily for 52 weeks
Also known as: Crestor
20 mg oral dose administered once daily for 4 weeks followed by 40 mg oral dose administered once daily for 48 weeks
Also known as: Crestor
40 mg oral dose administered once daily for 4 weeks followed by 80 mg oral dose administered once daily for 48 weeks
Also known as: Lipitor
Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes.
Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine protein/creatinine ratio over baseline urine protein/creatinine ratio.
Time frame: Assessed at Week 52, Last observation carried forward (LOCF)
Urinary Protein/Creatinine Ratio at Week 26.
Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine protein/creatinine ratio over baseline urine protein/creatinine ratio.
Time frame: Assessed at Week 26
Urinary Albumin/Creatinine Ratio at Week 26
Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.
Time frame: Assessed at Week 26
Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]
Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.
Time frame: Assessed at Week 52 LOCF
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26
Time frame: Assessed at Baseline and Week 26
Change From Baseline in eGFR at Week 52 [LOCF]
Time frame: Assessed at Baseline and Week 52 [LOCF]
Correlation Coefficient Urinary Protein/Creatinine Ratio and Total Cholesterol [TC] Indicating the Relationship Between Renal Effects and Lipid Changes
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52 (LOCF).
Time frame: 52 weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio TC
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: Assessed at 52 Weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Low Density Lipoprotein Cholesterol [LDL-C]
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and High Density Lipoprotein Cholesterol [HDL-C]
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and HDL-C
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Non-high Density Lipoprotein Cholesterol [nonHDL-C]
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Triglyceride [TG]
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TG
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein A-1 [ApoA-1]
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoA-1
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein B [ApoB]
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
Relationship Between Renal Effects and Lipid Changes: eGFR and TC
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: eGFR and TC
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 weeks
Relationship Between Renal Effects and Lipid Changes: eGFR and TG
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: eGFR and TG
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 weeks
Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 weeks
Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 weeks
Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 weeks
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 weeks
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 weeks
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 weeks
353 patients entered the study with Type 1 or 2 diabetes and were receiving current treatment with angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs). The study was conducted at 147 centers in 11 countries.
| Milestone | Rosuvastatin 10mg | Rosuvastatin 40mg | Atorvastatin 80mg |
|---|---|---|---|
| Started | 118 | 124 | 111 |
| Completed | 93 | 101 | 82 |
| Not completed | 25 | 23 | 29 |
| Withdrew: Adverse event | 14 | 10 | 7 |
| Withdrew: Withdrawal by subject | 3 | 5 | 11 |
| Withdrew: Incorrect enrollment | 3 | 3 | 4 |
| Withdrew: Protocol violation | 1 | 2 | 3 |
| Withdrew: Lost to follow-up | 3 | 1 | 1 |
| Withdrew: Relocated to another state | 1 | 0 | 0 |
| Withdrew: Stopped drug before end of study visit | 0 | 1 | 0 |
| Withdrew: Nephrologist introduced ace | 0 | 1 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 2 |
| Withdrew: Other | 0 | 0 | 1 |
Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine protein/creatinine ratio over baseline urine protein/creatinine ratio.
| mg/g | Rosuvastatin 10mg | Rosuvastatin 40mg | Atorvastatin 80mg |
|---|---|---|---|
| Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes. | 1.016 (0.858 to 1.209) | 0.955 (0.869 to 1.185) | 0.874 (0.733 to 0.975) |
Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine protein/creatinine ratio over baseline urine protein/creatinine ratio.
| mg/g | Rosuvastatin 10mg | Rosuvastatin 40mg | Atorvastatin 80mg |
|---|---|---|---|
| Urinary Protein/Creatinine Ratio at Week 26. | 1.007 (0.895 to 1.133) | 0.994 (0.881 to 1.121) | 0.876 (0.784 to 0.979) |
Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.
| mg/g | Rosuvastatin 10mg | Rosuvastatin 40mg | Atorvastatin 80mg |
|---|---|---|---|
| Urinary Albumin/Creatinine Ratio at Week 26 | 0.927 (0.792 to 1.085) | 0.913 (0.788 to 1.058) | 0.831 (0.726 to 0.951) |
Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.
| mg/g | Rosuvastatin 10mg | Rosuvastatin 40mg | Atorvastatin 80mg |
|---|---|---|---|
| Urinary Albumin/Creatinine Ratio at Week 52 [LOCF] | 1.016 (0.856 to 1.206) | 0.836 (0.704 to 0.993) | 0.823 (0.709 to 0.954) |
| mL/min | Rosuvastatin 10mg | Rosuvastatin 40mg | Atorvastatin 80mg |
|---|---|---|---|
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26 | -2.73 ± 12.644 | -5.46 ± 14.079 | -1.78 ± 10.997 |
| mL/min | Rosuvastatin 10 mg | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|---|
| Change From Baseline in eGFR at Week 52 [LOCF] | -3.70 ± 14.551 | -7.29 ± 20.040 | -1.61 ± 12.769 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52 (LOCF).
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Correlation Coefficient Urinary Protein/Creatinine Ratio and Total Cholesterol [TC] Indicating the Relationship Between Renal Effects and Lipid Changes | -0.03507 | 0.14258 | 0.01600 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio TC | 0.07019 | 0.26855 | 0.12013 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Low Density Lipoprotein Cholesterol [LDL-C] | -0.08588 | 0.18570 | -0.02491 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C | 0.04510 | 0.16280 | 0.06739 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and High Density Lipoprotein Cholesterol [HDL-C] | 0.15614 | 0.06987 | 0.14226 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and HDL-C | 0.16111 | 0.26194 | 0.18918 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Non-high Density Lipoprotein Cholesterol [nonHDL-C] | -0.12068 | 0.15929 | -0.05186 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C | 0.02594 | 0.24018 | 0.07381 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Triglyceride [TG] | -0.14569 | 0.04948 | -0.08471 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TG | -0.05251 | 0.11755 | 0.01345 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio | -0.13572 | 0.07339 | -0.08855 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio | -0.05945 | 0.12132 | -0.02666 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio | -0.13689 | 0.12931 | -0.08108 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio | -0.02775 | 0.06535 | -0.01569 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio | -0.16755 | 0.08891 | -0.11221 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio | -0.06085 | 0.12507 | -0.02841 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein A-1 [ApoA-1] | 0.15859 | 0.13133 | 0.15516 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoA-1 | 0.16587 | 0.18469 | 0.18832 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein B [ApoB] | -0.02276 | 0.21405 | 0.04578 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB | 0.05397 | 0.29486 | 0.11079 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio | -0.07846 | 0.13910 | -0.02825 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio | 0.00600 | 0.22710 | 0.03684 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC | 0.00642 | 0.14331 | 0.04311 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC | 0.13220 | 0.35715 | 0.18971 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C | -0.05514 | 0.19842 | 0.00038 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C | 0.10037 | 0.21205 | 0.12270 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C | 0.08593 | 0.00032 | 0.06930 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C | 0.14758 | 0.26805 | 0.17550 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C | -0.06694 | 0.17296 | -0.01144 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C | 0.09189 | 0.33769 | 0.14988 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG | -0.07271 | 0.08654 | -0.02876 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG | -0.02947 | 0.27198 | 0.08787 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio | -0.04785 | 0.11256 | -0.01362 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio | 0.01798 | 0.20127 | 0.05369 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio | -0.08211 | 0.16654 | -0.03001 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio | 0.03476 | 0.10902 | 0.04508 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio | -0.08468 | 0.12805 | -0.04102 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio | 0.01528 | 0.21198 | 0.05251 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1 | 0.14207 | 0.11171 | 0.13429 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1 | 0.16085 | 0.15933 | 0.17306 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB | -0.00569 | 0.20008 | 0.04833 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB | 0.10997 | 0.30537 | 0.15652 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio | -0.05906 | 0.13706 | -0.01775 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio | 0.04760 | 0.25636 | 0.07766 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: eGFR and TC | 0.01586 | -0.03124 | 0.00101 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: eGFR and TC | -0.13489 | -0.18105 | -0.14690 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C | 0.03010 | -0.00944 | 0.02609 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C | -0.11072 | -0.12835 | -0.11378 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C | 0.11373 | 0.01123 | 0.07576 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C | 0.14457 | -0.15546 | 0.08841 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C | -0.01709 | -0.05610 | -0.02569 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C | -0.17729 | -0.19501 | -0.17911 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: eGFR and TG | -0.10533 | -0.00604 | -0.09437 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: eGFR and TG | -0.24494 | -0.07059 | -0.15586 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio | -0.05426 | -0.01643 | -0.04256 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio | -0.26268 | -0.08593 | -0.23226 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio | -0.01040 | 0.00241 | 0.00189 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio | -0.19850 | -0.06481 | -0.17579 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio | -0.06356 | -0.04402 | -0.05499 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio | -0.26802 | -0.11804 | -0.24204 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1 | 0.08146 | 0.05333 | 0.05845 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1 | 0.17909 | 0.08090 | 0.12787 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB | -0.01427 | 0.08821 | 0.00737 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB | -0.15146 | 0.04886 | -0.12168 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio | -0.04088 | 0.06598 | -0.01652 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatment |
|---|---|---|---|
| Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio | -0.26146 | 0.05248 | -0.22109 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rosuvastatin 10mg | — | 18/116 (15.5%) | 15/116 (12.9%) |
| Rosuvastatin 40mg | — | 20/123 (16.3%) | 25/123 (20.3%) |
| Atorvastatin 80mg | — | 21/110 (19.1%) | 12/110 (10.9%) |
| Event | Rosuvastatin 10mg | Rosuvastatin 40mg | Atorvastatin 80mg |
|---|---|---|---|
| Cardiac FailureCardiac disorders | 3/116 | 1/123 | 1/110 |
| Angina PectorisCardiac disorders | 2/116 | 1/123 | 2/110 |
| Diabetes Mellitus Inadequate ControlMetabolism and nutrition disorders | 0/116 | 0/123 | 2/110 |
| Abortion SpontaneousPregnancy, puerperium and perinatal conditions | 0/116 | 0/123 | 2/110 |
| Oedema PeripheralGeneral disorders | 2/116 | 0/123 | 0/110 |
| Renal Failure AcuteRenal and urinary disorders | 0/116 | 2/123 | 0/110 |
| Acute Myocardial InfarctionCardiac disorders | 1/116 | 0/123 | 1/110 |
| Angina UnstableCardiac disorders | 0/116 | 0/123 | 1/110 |
| Atrial FibrillationCardiac disorders | 0/116 | 0/123 | 1/110 |
| Myocardial IschaemiaCardiac disorders | 0/116 | 0/123 | 1/110 |
| Event | Rosuvastatin 10mg | Rosuvastatin 40mg | Atorvastatin 80mg |
|---|---|---|---|
| Oedema PeripheralGeneral disorders | 9/116 | 5/123 | 3/110 |
| HypertensionVascular disorders | 2/116 | 8/123 | 2/110 |
| MyalgiaMusculoskeletal and connective tissue disorders | 3/116 | 6/123 | 7/110 |
| InfluenzaInfections and infestations | 3/116 | 7/123 | 0/110 |
| Age, Customized(Participants) | Rosuvastatin 10mg | Rosuvastatin 40mg | Atorvastatin 80mg | Total |
|---|---|---|---|---|
| 18-49 years | 22 | 33 | 25 | 80 |
| 50-64 years | 59 | 59 | 57 | 175 |
| >=65 years | 37 | 32 | 29 | 98 |
| Sex: Female, Male(Participants) | Rosuvastatin 10mg | Rosuvastatin 40mg | Atorvastatin 80mg | Total |
|---|---|---|---|---|
| Female | 43 | 32 | 33 | 108 |
| Male | 75 | 92 | 78 | 245 |
| Estimated glomerular filtration rate [eGFR](mL/min) | Rosuvastatin 10mg | Rosuvastatin 40mg | Atorvastatin 80mg | Total |
|---|---|---|---|---|
| Mean | 68.759 ± 24.1080 | 72.644 ± 25.8018 | 72.149 ± 24.8721 | 71.210 ± 24.9455 |
| Urine albumin/creatinine ratio(mg/g) | Rosuvastatin 10mg | Rosuvastatin 40mg | Atorvastatin 80mg | Total |
|---|---|---|---|---|
| Mean | 1036.478 ± 730.6185 | 1079.802 ± 725.7039 | 1143.198 ± 779.5282 | 1085.435 ± 743.5360 |
| Urine protein/creatinine ratio(mg/g) | Rosuvastatin 10mg | Rosuvastatin 40mg | Atorvastatin 80mg | Total |
|---|---|---|---|---|
| Mean | 1392.26 ± 888.3215 | 1493.574 ± 996.0972 | 1517.858 ± 969.7020 | 1467.843 ± 952.0380 |
Showing the first 100 of 116 sites across 11 countries. Choose a country and city above to see the rest.
The record gives a start of Feb 2006, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2010, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rosuvastatin